The Delhi High Court has issued a permanent injunction restraining Arlak Biotech Private Limited and Kuresia Pharma Private Limited from manufacturing, selling, or advertising nitroglycerin-controlled release tablets under the "Z-CONTIN" mark. In a decisive ruling delivered on November 4, 2026, Justice Vikas Mahajan granted a summary judgment in favour of Modi-Mundipharma Pvt. Ltd., finding that the defendants’ use of the disputed mark created a significant risk of consumer confusion regarding the pharmaceutical company’s long-standing "CONTIN" brand identity.

The legal battle stemmed from the plaintiff’s discovery in May 2025 that the defendants were marketing their nitroglycerin products using a nomenclature and trade dress that closely mimicked its established brand, "NITROCONTIN." Modi-Mundipharma, which holds over 80 registrations in Class 5 for products featuring the "CONTIN" suffix, successfully argued that this brand architecture represents an original artistic work and a well-known family of marks that have generated substantial goodwill over several decades. Beyond the trade name, the plaintiff highlighted that the defendants had adopted a similar pink-and-white colour scheme for their 2.6 mg dosage tablets, which it asserted was a clear attempt to trade upon its reputation.

Protecting the Integrity of Pharma Branding

Modi-Mundipharma’s case rested on its extensive investment in brand development and the consistent enforcement of its intellectual property rights. The company provided the court with comprehensive financial data demonstrating the commercial success of its "CONTIN" series, including figures from 2024 showing over ₹1.37 billion in domestic sales. The plaintiff argued that its vigilant enforcement history, which includes securing multiple judicial orders against other infringers, was essential to preventing market dilution and ensuring patient safety by avoiding medicinal confusion.

The litigation specifically targeted Arlak Biotech’s internal divisions—Soigner Pharma and Cardiac Vintage—and identified Kuresia Pharma as the current manufacturer of the offending products. While an initial cease-and-desist notice issued in May 2025 prompted a prior manufacturer, Gnosis Pharmaceuticals Pvt. Ltd., to formally undertake a cessation of production, the defendants chose not to engage with the court process. Despite being duly served with summons, Arlak Biotech and Kuresia Pharma failed to enter an appearance or file a written statement, leading the court to close their right to contest the claims and proceed with an ex-parte hearing.

Applying Summary Judgment in Commercial Disputes

The court’s decision to award a summary judgment under Order XIII-A of the Code of Civil Procedure, 1908, marked a significant procedural development in the case. By invoking the provisions applicable to commercial disputes, the bench determined that the defendants lacked any "real prospect" of successfully defending the claims. Justice Mahajan observed that the procedural silence of the defendants rendered the plaintiff's allegations uncontroverted, justifying a swift and final disposal of the suit without the necessity of a lengthy trial.

Drawing on established legal precedents, the court reasoned that allowing the infringing mark to remain in the marketplace would facilitate deception among unwary consumers. As the court noted in its final order: "Allowing the defendants to continue with the impugned mark can lead to a likelihood of confusion in the minds of general public as regards to the association of the defendants’ marks with that of the plaintiff."

This judicial stance underscored the importance of protecting the "CONTIN" series as a protectable class of trademarks. The court further relied on the principles articulated in previous rulings, such as DS Confectionary Products Limited v. Nirmala Gupta , which emphasized that the commercial court system is designed to provide efficient, time-bound resolutions. In the view of the court, since the material before it was sufficient to satisfy the requirements for both trademark infringement and passing off, further ex-parte evidence would have served only to delay justice.

Consequences for Infringing Manufacturers

In addition to the permanent injunction, the judgment provides a clear financial and operational deterrent. Modi-Mundipharma was awarded nominal damages amounting to ₹2 lakh, alongside the costs of the litigation. This penalty serves to penalize the defendants’ lack of compliance and their disregard for the court's processes. The court’s rejection of the defendants' actions aligns with its broader mandate to uphold the sanctity of registered trademarks and prevent the tarnishment of brands that have gained significant recognition within the healthcare sector.

The court's ruling concludes the proceedings in CS(COMM) 1087/2025, disposing of all pending applications in favour of the plaintiff. By cementing the protection of its "CONTIN" trademark family, Modi-Mundipharma has successfully reinforced its legal exclusivity in the market. The defendants are now under a permanent mandate to cease all manufacturing and promotional activities related to the "Z-CONTIN" mark, ensuring the protection of the brand’s integrity in the Indian pharmaceutical market moving forward. The final decree ensures that the plaintiff can seek immediate enforcement of its rights against any ongoing use of the infringing brand name or packaging by the identified parties.